Morrow Katherine L, Kim Ann H, Plato Steven A, Shevitz Andrew J, Goldstone Jerry, Baele Henry, Kashyap Vikram S
Department of Physiology and Biophysics, Case Western Reserve University, Cleveland, Ohio.
Division of Vascular Surgery and Endovascular Therapy, Harrington Heart and Vascular Institute, University Hospitals Case Medical Center, Cleveland, Ohio.
J Vasc Surg. 2017 May;65(5):1460-1466. doi: 10.1016/j.jvs.2016.09.047. Epub 2016 Nov 19.
Percutaneous mechanical thrombectomy (PMT) is regularly used in the treatment of both venous and arterial thrombosis. Although there has been no formal report, PMT has been linked to cases of reversible postoperative acute kidney injury (AKI). The purpose of this study is to evaluate the risk of renal dysfunction in patients undergoing PMT vs catheter-directed thrombolysis (CDT) for treatment of an acute thrombus.
This study is a retrospective review of all patients in a single institution with a Current Procedural Terminology code for PMT or CDT from January 2009 through December 2014. Each patient was grouped into one of the four following procedural categories: PMT only, PMT with tissue plasminogen activator (tPA) pulse-spray, PMT with CDT, or CDT only. Preoperative and postoperative creatinine and glomerular filtration rate (GFR) values were obtained for each patient. The RIFLE (Risk, Injury, Failure, Loss, and End-stage renal disease) criteria were used to categorize the extent of renal dysfunction. χ analysis, one-way analysis of variance, and unpaired t-test were used to assess significance.
A total of 227 patients were reviewed, of which 82 were excluded due to either existence of preoperative AKI, history of end-stage renal disease, or lack of clinical data. Of the remaining 145 patients, 53 (37%) presented with arterial thrombosis (mean age, 62 years; 43% male) and 92 (63%) presented with venous thrombosis (mean age, 48 years; 45% male). The incidence of renal dysfunction was highest in the PMT/tPA pulse group (21%), followed by the PMT group (20%) and the PMT/CDT group (14%). CDT was not associated with renal dysfunction. PMT (P = .046), and PMT/tPA pulse (P = .033) were associated with higher rates of renal dysfunction than the CDT controls. The average preoperative GFR for the 22 patients who developed AKI was 53.7 ± 9.4 mL/min/1.73 m. The minimum postoperative GFR within 48 hours was an average of 35 ± 16 mL/min/1.73 m. Stratified by the RIFLE criteria, 13 (9%) patients progressed to the risk category, 6 (4%) progressed to the injury category, and 3 (2%) progressed to the failure category. None of the patients who developed renal dysfunction from PMT progressed to dialysis within the same admission period.
The use of PMT as a treatment for vascular thrombosis is associated with renal dysfunction. Patients treated with PMT require postoperative vigilance and renal protective measures.
经皮机械血栓切除术(PMT)常用于治疗静脉和动脉血栓形成。虽然尚无正式报告,但PMT已与术后可逆性急性肾损伤(AKI)病例相关。本研究的目的是评估接受PMT与导管定向溶栓(CDT)治疗急性血栓的患者发生肾功能障碍的风险。
本研究是对一家机构中2009年1月至2014年12月期间具有PMT或CDT现行程序术语代码的所有患者进行的回顾性研究。每位患者被分为以下四个程序类别之一:仅PMT、PMT联合组织型纤溶酶原激活剂(tPA)脉冲喷射、PMT联合CDT或仅CDT。获取每位患者术前和术后的肌酐及肾小球滤过率(GFR)值。采用RIFLE(风险、损伤、衰竭、丧失和终末期肾病)标准对肾功能障碍的程度进行分类。使用χ分析、单因素方差分析和非配对t检验来评估显著性。
共回顾了227例患者,其中82例因术前存在AKI、终末期肾病病史或缺乏临床数据而被排除。在其余145例患者中,53例(37%)表现为动脉血栓形成(平均年龄62岁;43%为男性),92例(63%)表现为静脉血栓形成(平均年龄48岁;45%为男性)。肾功能障碍发生率在PMT/tPA脉冲组最高(21%),其次是PMT组(20%)和PMT/CDT组(14%)。CDT与肾功能障碍无关。与CDT对照组相比,PMT(P = 0.046)和PMT/tPA脉冲(P = 0.033)与更高的肾功能障碍发生率相关。发生AKI的22例患者术前平均GFR为53.7±9.4 mL/min/1.73m²。术后48小时内的最低GFR平均为35±16 mL/min/1.73m²。根据RIFLE标准分层,13例(9%)患者进展至风险类别,6例(4%)进展至损伤类别,3例(2%)进展至衰竭类别。在同一住院期间,因PMT发生肾功能障碍的患者均未进展至透析。
使用PMT治疗血管血栓形成与肾功能障碍相关。接受PMT治疗的患者术后需要进行监测并采取肾脏保护措施。